Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CurveBeam AI has received multiple regulatory clearances including FDA 510(k), CE Mark, and Health Canada approvals for its cone beam CT systems. The company’s solutions are commercially available globally and are used in clinical practice to improve orthopedic diagnostic accuracy and patient outcomes. In July 2024, the company received special FDA clearance for an enhanced X-ray source in its HiRise system.
Its deep learning platforms support advanced bone segmentation and microstructure analysis to aid clinicians in diagnosis and treatment planning.
No drug or therapeutic clinical trial results apply as the company focuses on devices/software.
Pipeline breadth reflects ongoing product development/AI enhancements rather than traditional drug pipelines.
The merger with StraxCorp expanded their R&D capabilities into advanced bone health analytics using artificial intelligence.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CurveBeam AI.